China insulin aspart market dominated by Novo Nordisk, but for how long?

Developed by Danish diabetes care giant Novo Nordisk (NOV: N), insulin aspart (under the trade name of NovoLog) is an important drug for the treatment of diabetes, notes a new report from Research and Markets.

Compared with human insulin, insulin aspart, as a fast-acting insulin analog, starts working fast and reports higher peak of glucose-lowering action and lower risk of hypoglycemia. Even though insulin aspart for injection was approved to enter China in 2012, it has been in the market for over a decade.

Although this market is currently dominated by the Novo Nordisk product, some local enterprises are trying to make generic drugs.